Moreover, in the whole RA cohort, there were no significant differences in terms of pre-treatment STAT3 and STAT5 expression in peripheral blood-derived CD4pos cells based on the achievement of DAS- and CDAI-defined remission at 6 months of treatment with CTLA4-Ig (Fig. 3C, D). The gene discussed is STAT3; the disease is rheumatoid arthritis.